Genmab — August 2024
-
Merck Axes Two Keytruda Phase III Cancer Trials Due to Disappointing Data
The pharma continued its clinical losing streak on Thursday with the announcement that it is discontinuing late-stage studies of the anti-PD-1 therapy in non-small cell lung cancer and cutaneous squamous cell carcinoma.
BioSpace (www.biospace.com)
-
@Darvin 18.29. Jeg forbeholder mig min ret til at omtale min hustru som have værende en dejlig dame. .... Pas nu på, at skoene ikke bliver for små - sårklemmer de
-
Genmab får kursmålet sat ned af Deutsche til 2500 kr. fra 2750 kr https://proinvestor.com/investornyt/1207168/genmab-far-kursmalet-sat-ned-af-deutsche-til-2500-kr-fra-2750-kr
-
JW trækker sig også i Hookipa https://finance.yahoo.com/news/hookipa-pharma-announces-board-directors-120000078.html
-
Gebmab kun nr. 19 "Private investorer sætter sig tungt på C25-selskab: Ejer nu over 40 pct." https://borsen.dk/nyheder/investor/private-danskere-satser-stort-paa-enkeltaktier-her-er-deres-favoritter?b_source=borsen&b_medium=row_0&b_campaign=news_1
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind